STAT+: Pharmalittle: Roche to buy obesity-drug developer for $2.7 billion; Novo Nordisk paid U.S. doctors $26 million over a decade
The booming obesity market is attracting another player, as Roche plans to acquire Carmot Therapeutics and its weight loss drug candidates.
Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and refreshing, because that oh-so familiar routine of online meetings, phone calls, and deadlines has predictably returned.
